Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FBXW7 |
Variant | T15_G16insTP |
Impact List | insertion |
Protein Effect | unknown |
Gene Variant Descriptions | FBXW7 T15_G16insTP results in the insertion of two amino acids in the Fbxw7 protein between amino acids 15 and 16 (UniProt.org). T15_G16insTP has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Jul 2024). |
Associated Drug Resistance | |
Category Variants Paths |
FBXW7 mutant FBXW7 T15_G16insTP |
Transcript | NM_033632.3 |
gDNA | chr4:g.152411760_152411761insGTGTAG |
cDNA | c.45_46insACACCT |
Protein | p.T15_G16insTP |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_047415900.1 | chr4:g.152411760_152411761insGTGTAG | c.45_46insACACCT | p.T15_G16insTP | RefSeq | GRCh38/hg38 |
XM_011532085 | chr4:g.152411760_152411761insGTGTAG | c.45_46insACACCT | p.T15_G16insTP | RefSeq | GRCh38/hg38 |
XM_047415898.1 | chr4:g.152411760_152411761insGTGTAG | c.45_46insACACCT | p.T15_G16insTP | RefSeq | GRCh38/hg38 |
XM_017008362 | chr4:g.152411760_152411761insGTGTAG | c.45_46insACACCT | p.T15_G16insTP | RefSeq | GRCh38/hg38 |
XM_011532084 | chr4:g.152411760_152411761insGTGTAG | c.45_46insACACCT | p.T15_G16insTP | RefSeq | GRCh38/hg38 |
NM_033632.3 | chr4:g.152411760_152411761insGTGTAG | c.45_46insACACCT | p.T15_G16insTP | RefSeq | GRCh38/hg38 |
XM_024454123.1 | chr4:g.152411760_152411761insGTGTAG | c.45_46insACACCT | p.T15_G16insTP | RefSeq | GRCh38/hg38 |
XM_024454123.2 | chr4:g.152411760_152411761insGTGTAG | c.45_46insACACCT | p.T15_G16insTP | RefSeq | GRCh38/hg38 |
NM_001257069.1 | chr4:g.152411760_152411761insGTGTAG | c.45_46insACACCT | p.T15_G16insTP | RefSeq | GRCh38/hg38 |
NM_033632.3 | chr4:g.152411760_152411761insGTGTAG | c.45_46insACACCT | p.T15_G16insTP | RefSeq | GRCh38/hg38 |
XM_024454124.1 | chr4:g.152411760_152411761insGTGTAG | c.45_46insACACCT | p.T15_G16insTP | RefSeq | GRCh38/hg38 |
XM_047415901.1 | chr4:g.152411760_152411761insGTGTAG | c.45_46insACACCT | p.T15_G16insTP | RefSeq | GRCh38/hg38 |
NM_033632 | chr4:g.152411760_152411761insGTGTAG | c.45_46insACACCT | p.T15_G16insTP | RefSeq | GRCh38/hg38 |
NM_001257069 | chr4:g.152411760_152411761insGTGTAG | c.45_46insACACCT | p.T15_G16insTP | RefSeq | GRCh38/hg38 |
NM_001257069.1 | chr4:g.152411760_152411761insGTGTAG | c.45_46insACACCT | p.T15_G16insTP | RefSeq | GRCh38/hg38 |
NM_001349798.1 | chr4:g.152411760_152411761insGTGTAG | c.45_46insACACCT | p.T15_G16insTP | RefSeq | GRCh38/hg38 |
XM_011532084.2 | chr4:g.152411760_152411761insGTGTAG | c.45_46insACACCT | p.T15_G16insTP | RefSeq | GRCh38/hg38 |
XM_047415899.1 | chr4:g.152411760_152411761insGTGTAG | c.45_46insACACCT | p.T15_G16insTP | RefSeq | GRCh38/hg38 |
XM_047415897.1 | chr4:g.152411760_152411761insGTGTAG | c.45_46insACACCT | p.T15_G16insTP | RefSeq | GRCh38/hg38 |
XM_011532085.3 | chr4:g.152411760_152411761insGTGTAG | c.45_46insACACCT | p.T15_G16insTP | RefSeq | GRCh38/hg38 |
NM_001349798.2 | chr4:g.152411760_152411761insGTGTAG | c.45_46insACACCT | p.T15_G16insTP | RefSeq | GRCh38/hg38 |
XM_011532085.2 | chr4:g.152411760_152411761insGTGTAG | c.45_46insACACCT | p.T15_G16insTP | RefSeq | GRCh38/hg38 |
XM_024454121.1 | chr4:g.152411760_152411761insGTGTAG | c.45_46insACACCT | p.T15_G16insTP | RefSeq | GRCh38/hg38 |
XM_011532084.3 | chr4:g.152411760_152411761insGTGTAG | c.45_46insACACCT | p.T15_G16insTP | RefSeq | GRCh38/hg38 |
XM_024454122.1 | chr4:g.152411760_152411761insGTGTAG | c.45_46insACACCT | p.T15_G16insTP | RefSeq | GRCh38/hg38 |
XM_011532083 | chr4:g.152411760_152411761insGTGTAG | c.45_46insACACCT | p.T15_G16insTP | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FBXW7 mutant | Her2-receptor negative breast cancer | predicted - sensitive | LY3039478 | Case Reports/Case Series | Actionable | In a Phase I trial, LY3039478 treatment resulted in partial response lasted 9.5 months in a patient with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer harboring FBXW7 mutation (PMID: 30060061; NCT01695005). | 30060061 |